AA amyloidosis in inflammatory joint diseases in the era of biological therapies: Prevalence, manifestations, management and evolution
Authors' conclusion
In the last 2 decades, AAA occurred in only patients with IJDs who experienced long diagnostic and therapeutic delays, mainly related to country of origin and difficulties in access to care.
Study context
- Population
- Adults with inflammatory joint diseases followed 2008–2025 in 2 French tertiary university hospitalsIJD-related AAA
- Participants
- 15 adults
- Exposure
- RA vs Spondylarthritis vs JIA vs Undifferentiated arthritis vs Gout
- RAn = 5
- Spondylarthritisn = 4
- JIAn = 2
- Undifferentiated arthritisn = 3
- Goutn = 1
- Outcome
- Prevalence, manifestations, management and evolution of AAA in inflammatory joint diseases (IJDs)
Methodological details2 French tertiary university hospitals, histologically confirmed AAA
- 2 French tertiary university hospitals
- Histologically confirmed AAA
Main finding
As reported in the abstract
Prevalence of AAA
RA
0.6‰
Spondylarthritis
0.5‰
Observational data: associations, not effects.
Further findings
Patient characteristics at AAA diagnosis
- From developing countries
- 10 (66.7%)
- Not receiving any IJD treatment
- 80%
- Delays in diagnosis and treatment
- all patients
- CRP, median (IQR)
- 41.5 (16.8-59.5) mg/L
- Serum amyloid A, median (IQR)
- 31 (13-44) mg/L
- Proteinuria/creatinuria ratio, median (IQR)
- 3.5 (1.3-5.2) g/mmol
- Manifestations mainly renal and digestive
Response to bDMARD (started in 14; 1 lost to follow-up)
- Clinically inactive disease
- 57.2%
- Normal CRP and serum amyloid A and proteinuria negativity
- 71.4%
Original publication
AA amyloidosis in inflammatory joint diseases in the era of biological therapies: Prevalence, manifestations, management and evolution. Joint Bone Spine. Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →